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Abstract 
Purpose: To analyze the therapeutic indications for off-label use of rituximab, 
the available evidence for its use, the outcomes, and the cost. 
Methods: Retrospective analysis of patients treated with rituximab for off-label 
indications from January 2007 to December 2009 in two tertiary hospitals. 
Information on characteristics of patients, medical conditions and therapeutic 
responses was collected from medical records. Available evidence for the 
efficacy of rituximab in each condition was reviewed and the cost of treatment 
was calculated. 
Results: A total of 101 cases of off-label rituximab use were analyzed (median 
[IQR] age 53 years [37.5-68.0]; 55.4% women). The requested indications were 
mainly haematological diseases (46%), systemic connective tissue disorders 
(27%) and kidney diseases (20%). Available evidence in these indications were 
mainly individual cohort studies (53.5% of cases), and case series (25.7%). 
Short-term outcome (median 3 months [IQR 2-4]) was a complete response in 
38% of cases and partial response in 32.6%. The highest short-term responses 
were observed for systemic lupus erythematosus and membranous 
glomerulonephritis, and the lowest for neuromyelitis optica, idiopathic 
thrombocytopenic purpura, and miscellaneous indications. Some response was 
maintained in long-term follow-up (median 23 months [IQR 12-30]) in 69.2% of 
patients with short-term response. Median cost per patient was € 5,187.5 (IQR 
5,187.5-7,781.3). 
Conclusions: Off-label rituximab is mainly used for the treatment of 
haematological, kidney and systemic connective tissue disorders, and the 
response was variable depending on the diseases. The level of evidence in 
these indications was low and the cost very high. More clinical trials are 
needed, although they can be difficult in some rare diseases. Data from 
observational studies may provide useful information to assist prescribing in 
clinical practice.  
 
Keywords: “Drug therapy”; “Off-label use”; “Efficiency”; “Pharmacy and 
Therapeutics Committees”; “Rituximab”.  
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INTRODUCTION 
 
In Spain the regulation for off-label drug prescriptions changed in 2009. The 
change has allowed the use of drugs for unapproved indications to be taken by 
the prescribing physician and the patient, who must consent to treatment after 
being properly informed [1]. Off-label use should be an exception and limited to 
situations in which there is a lack of approved alternatives for a particular 
patient. Authorization from the Regulatory Agency is not required now. Although 
the procedure is easier, this may facilitate the use of drugs with less conclusive 
evidence of efficacy, with greater uncertainty regarding their toxicity and often at 
a high cost. This worries hospital medical directors and health managers, 
because they can have doubts about the adequacy of financing drugs with 
insufficient or very limited data on efficacy. That’s why, in accordance with the 
Catalan Health Service procedures [2], the Pharmacotherapeutics Committees 
in the public hospitals assess each case in order to verify if they fulfil the above 
conditions and to advise the Medical Directors. 
 
Rituximab is one of the most frequently requested off-label drugs in our 
hospitals [3]. Rituximab is the first anti-CD20 monoclonal antibody to be 
marketed. CD20 antigen regulates the early steps of activation and 
differentiation of B lymphocytes [4]. Rituximab was approved by the EMA in 
1998 to be used in patients with stage III-IV follicular lymphoma who are 
chemoresistant or are in their second or subsequent relapse after 
chemotherapy. Since then, EMA indications for rituximab have broadened and 
can be used in first line treatment and maintenance of previously specified 
types of lymphoma. It has also been approved for CD20 positive diffuse large B 
cell non-Hodgkin’s lymphoma in combination with CHOP chemotherapy, 
rheumatoid arthritis, and chronic lymphocytic leukemia [5].  
 
Nevertheless, there is an increasing use of rituximab in off-label haematological 
and non-haematological conditions, where B-cells and autoantibodies are 
thought to play an important role in their pathophysiology. Although several 
authors have analyzed the off-label use of rituximab in patients with specific 
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diseases, mainly systemic lupus erythematosus, lupus nephritis and other 
severe refractory systemic autoimmune diseases [6-12], data on its use in 
different off-label indications are scarce [13-15]. The aim of this study was to 
analyze the indications for off-label use of rituximab in our centres, the available 
evidence when it was used, the outcomes of treated patients, as well as the 
cost. 
 
 
METHODS 
 
A retrospective longitudinal study of patients treated with rituximab for off-label 
indications from January 2007 to December 2009 in two tertiary hospitals in the 
Spanish public health system (H. Universitari Vall d’Hebron and Hospital 
Universitari de Bellvitge) was carried out. Patients treated with rituximab were 
identified from a Pharmacy register of requests for its off-label use. A 
retrospective review of medical records was conducted to get information about 
the patients (demographic data), their disease (indication for rituximab use, 
clinical, biological and image data to analyze its stage), dosage and treatment 
regimen of rituximab, previous and concurrent treatments, and outcome in short 
and long-term after treatment with rituximab. Patients' information and their 
clinical progress before and after rituximab treatment were verified conducting 
an audit of clinical records and consulting the clinicians responsible for patients 
care. Response was defined for each disease as complete (CR), partial (PR) or 
no response (NR) taking into account different parameters for each disease. In 
lupus nephritis and other glomerulonephritis, outcome measures included 
mainly proteinuria (CR: proteinuria ≤ 500 mg/24 h; PR: improvement ≥ 50%). In 
patients with systemic lupus erythematosus, symptoms and scores of disease 
activity were considered (CR: Systemic Lupus Erythematosus Disease Activity 
Index [SLEDAI] ≤4 or clinical remission; PR: improvement ≥50% in SLEDAI). In 
patients with non-Hodgkin lymphoma response was assessed with 
hematological parameters and computerized tomography (CR: normalization of 
nodes, spleen, liver and biochemistry; PR: decrease of lymph node size ≥50%) 
[16], and in patients with idiopathic thrombocytopenic purpura, the main 
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outcome was the number of platelets (CR: platelet count > 150 x 109/L; PR: 
platelet count > 50 x 109/L).   
 
A search in PubMed was performed to assess the available evidence of 
rituximab in each clinical indication when it was requested. Available evidence 
for each disease was classified according to Oxford Centre for Evidence-based 
Medicine criteria [17]. In addition, information on ongoing clinical trials for each 
indication of rituximab was obtained from the clinicaltrials.gov register [18]. 
ICD10 version was used to classify medical indications for rituximab use. To 
analyze the cost of treatment, the price of the drug marketed in Spain 
(Mabthera®) at the time of the study was taken into account. The total cost of 
treatment administered during the study period for each patient and for each 
indication was calculated. 
 
The study was conducted according to international ethical recommendations. 
In accordance with the national directives in relation to post-authorization 
studies, the study was approved by the Ethics Committee of Clinical 
Investigation in each participating hospitals. 
 
Descriptive analysis of categorical and continuous variables was performed by 
means of the distribution of frequencies and proportions, median and 
interquartile range. Statistical differences were assessed using the chi-square 
test. Significance was set at a level of 0.05, and was two-tailed. The statistical 
analysis was performed using IBM SPSS Statistics version 19 statistical 
package (SPSS, Chicago, IL,USA). 
 
 
RESULTS 
 
One hundred and one cases of off-label use of rituximab were identified and 
included in the study. All the patients were adult, with a median age of 53 years 
(interquartile range [IQR] 37.5-68.0), and 55.4% were female. The main medical 
specialities of prescribers were Haematology (33.7%), Internal Medicine 
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(30.7%), and Nephrology (21.8%). The requested indications for rituximab use 
were haematological neoplasms (33%) and other haematological diseases 
(13%), systemic connective tissue disorders, including lupus nephritis (27%), 
kidney (20%) and neurologic diseases (7%) (see table 1). 
 
Most patients (97%) had received other treatments before the request for 
rituximab off-label use. The median number of previous pharmacological 
treatments was 3 (IQR 2-4), and for haematological conditions treated with 
chemotherapy the median number of previous regimens was 2.5 (IQR 1-3).  
 
Available evidence for rituximab use in these off-label indications was level 2b 
(based on individual cohort study) in 53.5% of cases, level 4 (based on case 
series) in 25.7%, level 2a (systematic review of cohort studies) in 10.9% of 
cases, level 1a (systematic review of randomized controlled trials) in 8.9%, and 
level 5 (based on expert opinion) in only 1% of cases. Table 1 shows the levels 
of the available evidence for rituximab in the requested conditions. A level of 
evidence 1a or 2a was available in 42.5% of haematological cases and in none 
of the other cases. In the majority of indications some clinical trials were 
ongoing: phase 3 trials for 69.3% of requests and phase 2 for 15.8% (see table 
1).  
 
In 7 cases rituximab was not administered despite the request. In chronic 
lymphocytic leukemia and in the majority of lymphoma cases, the most 
commonly prescribed dose was 375 mg/m2 for 6-8 cycles (the median number 
of administered cycles was 4). In the other diseases the dose was 1 g IV two 
weeks apart in 37 cases or 375 mg/m2 weekly for 4 weeks in 12 cases.   
 
The short-term outcome, after a median period of 3 months (IQR 2-4), was 
available for 92 cases (2 were lost in follow up), and the observed outcome was 
classified as complete response in 35 cases (38%) and partial in 30 (32.6%). 
Therefore, some response was observed in 65 (70.6%) patients and no 
response in 27 (29.4%). The observed outcome depending on the disease is 
shown in table 2. The highest short-term responses, complete or partial, were 
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observed in patients with systemic lupus erythematosus, follicular non-Hodgkin 
lymphoma and membranous glomerulonephritis (100% of cases), mantle-cell 
non-Hodgkin lymphoma (83.3%) and lupus nephritis (77.8%). Meanwhile, the 
lowest short-term response was observed for neuromyelitis optica and 
idiopathic thrombocytopenic purpura (50%), large B-cell non-Hodgkin 
lymphoma (40%), and the pooling of miscellaneous indications (36%). 
 
The median long-term follow-up period was 23 months (IQR 12-30). In long-
term period, 45 out of 65 patients with short-term response (69.2% of them and 
almost half of the total) maintained some effectiveness (29 complete response 
and 16 partial response), although 19 patients continued receiving other 
treatments or additional doses of rituximab. The long-term response was low in 
some haematological conditions such as chronic lymphocytic leukemia (27.3%) 
and mantle-cell non-Hodgkin lymphoma (0%). In contrast, long-term outcome of 
patients with membranous glomerulonephritis (83.3%), follicular non-Hodgkin 
lymphoma (75%), and lupus nephritis (72.2%) was high. A more detailed 
description of demographics and clinical course of patients with the most 
frequent diseases are shown in table 3. A relationship was found between the 
level of available evidence and the short-term outcome: some response 
(complete or partial) was described in 77.6% of cases of diseases with a high 
level of evidence (1 or 2) and in 52% of cases with a lower level of evidence 
(p=0.016).  
 
At least one adverse reaction was described in medical records in 27.7% of 
patients. A total of 47 adverse reactions were registered. The most commonly 
reported were nausea, vomiting, diarrhoea, pyrexia, sepsis, constipation, 
urinary tract infection and neutropenia. Eleven adverse effects (23.4%) were 
considered serious: 7 infections, 2 cases of gastrointestinal bleeding, oedema 
(1) and mucositis (1); in 8 of these cases the patient was also treated with 
chemotherapy. In 4 patients treatment was discontinued due to the adverse 
drug reaction.  
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The total budget for rituximab treatment during the study period was € 
677,901.18, and the median cost per patient was € 5,187.5 (IQR 5,187.5-
7,781.3). The most expensive indications were neuromyeltis optica, with a 
median cost of € 14,151.3 (IQR 5,332.6-31,820.1), and mantle-cell non-Hodgkin 
lymphoma (6,948.7; IQR 5,524.7-12,450); the cheapest were those in which the 
drug is administered locally, such as conjunctival MALT lymphoma (€ 52) and 
marginal zone lymphoma of the skin (€ 521,7). Median cost during the study 
was slightly higher for patients with diseases with a low level of evidence (3 or 
less) for rituximab (5,477.6; IQR 3,912.6-7,781.3) than for those with a high 
level of evidence (5,187.5; 5,187.5-8,083.3). The total cost of non-responders 
was € 171,245.37 (25.3% of the total budget).  
 
 
DISCUSSION 
 
The results of the study show that off-label use of rituximab was mainly for the 
treatment of haematological, kidney and systemic connective tissue disorders.  
Available evidence for rituximab in these diseases was low, because it was 
mainly based on cohort studies and case series, while in most cases phase 3 or 
2 clinical trials were ongoing at that time. The short-term response was quite 
good, taking into account that patients were usually refractory to other 
treatments, and almost half of the total maintained this response long-term. 
Nevertheless, the response was variable according to the different indications. 
Off-label use of rituximab was very expensive. Off-label use of rituximab in 
different indications has also been assessed in other studies [13-15], although 
this study is the largest one in which evidences-based indications as well as 
patients' short and long-term outcomes and cost have been evaluated.  
 
Haematological diseases were also frequent off-label indications of rituximab in 
other studies [14, 15]. Nevertheless, in our study non-haematological 
indications such as kidney and systemic connective tissue diseases have also 
been frequent. These results are in accordance with an increasing use of 
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rituximab in other non-haematological off-label conditions where humoral 
immunity appear to play a role in their pathophysiology [13]. 
 
Few studies have assessed the level of evidence of off-label rituximab use. In 
the study of van Allen et al [14], in which different criteria for stratifying evidence 
were used, 47.1% of rituximab off-label administrations were classified with 
uncertain or inadequate levels of evidence and 52.9% with an adequate 
evidence-base for use. In our study, at the moment of the rituximab off-label 
request, the level of its published evidence was low and varied according to the 
diseases, and for most conditions phase 3 or 2 clinical trials were ongoing. 
These results suggest that although some kind of research is being carried out, 
decisions regarding off-label use of rituximab are difficult with the available 
evidence at the moment of off-label request.  
 
The response rate in our study is comparable to that reported in other similar 
studies [13], also conducted in tertiary hospitals. It is noteworthy that in our 
study the overall rate of response includes the rituximab use in diseases that 
are currently approved, but that were not authorized when they were requested 
as off-label use. Nevertheless, the exclusion of these indications did not modify 
the overall response rate (71.2%). Results observed in patients with follicular 
non-Hodgkin lymphoma were in accordance with those of clinical trials [19], 
although it was administered with a non-authorized combination with 
bendamustine. In patients with chronic lymphocytic leukemia the response rate 
decreased in the long-term follow-up. In a randomized clinical trial using 
rituximab and chemotherapy, after a median follow-up of two years, a 
significantly improved progression-free survival and response rate was 
observed in patients who had been previously treated for chronic lymphocytic 
leukemia [20]. The differences between these findings and our results may be 
due to the patients' characteristics; in our study patients were older, and the 
majority of them (82%) had previously been treated with two or more 
chemotherapeutic regimens. Otherwise, the outcomes of most patients with 
diffuse large B-cell non-Hodgkin lymphoma were disappointing. Early clinical 
trials have shown that the addition of rituximab to the CHOP regimen increases 
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the complete-response rate and prolongs event-free and overall survival in 
elderly patients with this condition [21-23]. Once again, the poor results 
observed in our study might be explained by the fact that the prognosis was 
worse in our cases, including people who had relapsed or had a refractory 
disease, and because rituximab was given in combination with other 
chemotherapies (gemcitabine and oxaliplatin). 
    
For other diseases, rituximab is not approved but some clinical trials have 
recently been published. In patients with mantle-cell non-Hodgkin lymphoma, 
the short-term partial and complete response rate was high, but their long-term 
responses were null, as usual. This is in accordance with the published results 
[19]. Recently, the results of a clinical trial have shown that rituximab in 
combination with chemotherapy followed by maintenance therapy with rituximab 
may improve the overall long-term survival in older patients with mantle-cell 
lymphoma [24]. 
 
Two clinical trials with rituximab in patients with lupus have not confirmed the 
efficacy suggested by case-series and recent cohort studies [6-12]. In the 
EXPLORER trial that included patients with moderately-to-severely active 
systemic lupus erythematosus, no differences in the proportion of patients 
achieving and maintaining a partial or complete response were found between 
rituximab and placebo [25]. These results contrast with those of our study but 
criteria used in this trial differ from ours. Refractory patients and those recently 
treated with a cyclophosphamide or a calcineurin inhibitor were excluded in this 
trial. However, most of these patients were included in our study and other 
open-label studies and case reports [26]. Furthermore, the LUNAR trial that 
included patients diagnosed as having lupus nephritis class III or IV did not find 
any differences in the overall response rate between rituximab and placebo 
[27]. Criteria used to assess the efficacy in this trial also differ from our ones, as 
well as the severity of patients. Although in our study the patients were also 
diagnosed with lupus nephritis class III or IV and treated with mycophenolate 
mofetil and corticosteroids, they had a longer and more serious history of 
disease than patients included in the LUNAR trial. Furthermore, the high 
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response rate reported in the placebo arm may partially be explained by the fact 
that their patients were not as seriously ill as ours [28]. Given these results, it 
would be reasonable to support the use of rituximab in patients with lupus in the 
setting of a clinical trial in refractory population. 
 
In adults with previously untreated primary immune thrombocytopenia, one 
clinical trial has been published [29]. Sustained response (ie, platelet count > or 
= 50 x 109/L after a 6 month follow-up period) was significantly greater in 
patients treated with dexamethasone and rituximab than in those treated with 
dexamethasone alone (63% vs 36%, respectively). In a systematic review of 
observational studies rituximab resulted in a pooled response rate of 62.5% with 
a median duration of response of 10.5 months [30]. The response rate in our 
study was lower and decreased in the long-term follow-up, but rituximab was 
used once again almost as the last pharmacological resource.  
 
Rituximab off-label use was commonly requested in kidney diseases such as 
glomerulonephritis, the membranous glomerulonephritis being the most 
frequent. We have observed good short-term and long-term results as far as 
proteinuria is concerned in these patients, although some of them received 
additional doses of rituximab to maintain a lasting response. In a systematic 
review of case reports and case series that included 85 patients diagnosed with 
membranous glomerulonephritis treated with rituximab, a 15 to 20% rate of 
complete remission and a 35 to 40% rate of partial remission were reported 
[31]. Now some clinical trials have been completed, but no results have been 
published to date.  
 
Rituximab is very expensive and the treatment of all cases in our study had a 
significant cost as has been reported in other studies [13, 14]. Cost is a matter 
of controversy in off-label drug uses, because the available evidence of cases is 
usually scarce and their cost-benefit rate is often uncertain. The use of off-label 
drugs can be controversial. Health managers, doctors, the pharmaceutical 
industry and patients can have different expectations, and we need to make 
reliable decisions. Physicians believe that their use may be justified by the poor 
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prognosis of patients and the inability of achieving good results with alternative 
treatments, and patients want to be cured. The pharmaceutical industry is 
interested in promoting the use of their drugs as much as possible, even in off-
label indications [32]. Health managers are reluctant to reimburse the cost of 
those treatments with such little scientific evidence supporting its use [33]. The 
off-label use of costly drugs requires a careful evaluation of cases and 
reasonable expectations regarding clinical outcome. Clinical trials should be 
done to assess the efficacy of rituximab in off-label indications, but funding trials 
in rare diseases can be difficult. Meanwhile, it would seem reasonable to treat 
particularly severe cases unresponsive to other therapy with a possibly effective 
drug albeit evidence is incomplete. In the absence of randomised clinical trials, 
the results of prospective registries of patients treated in these conditions or 
observational studies similar to this present may be useful. 
 
This study has some limitations. Firstly, it is an observational study with a 
retrospective design and without a control group. Therefore the results might be 
biased. Secondly, we included a heterogeneous group of diseases with few 
cases in each group and, consequently, we have limited information. Finally, 
only two centres were included in the study. As a result, our findings could not 
be extrapolated to other hospitals in other geographical areas. However, as a 
main strength, this is the largest study in which evidence-based indications, 
patients’ outcomes and cost of different off-label use of rituximab has been 
assessed. Moreover, in our study the outcome survey was longer than in 
others, and the centres participating were two large tertiary teaching hospitals, 
with all medical and surgical specialities, and high a level of complexity. 
  
In conclusion, indications for the off-label use of rituximab were variable, 
although haematological, kidney and systemic connective tissue diseases were 
the main indications. Available evidence for rituximab in most of these settings 
was low, but there were ongoing clinical trials assessing its efficacy. In general, 
short-term response was quite good, bearing in mind that patients were usually 
refractory to other treatments, and almost half of them maintained long-term 
response. In the absence of strong evidence, and taking into account that 
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clinical trials can be difficult in some rare diseases, data from prospective 
registers and observational studies of patients treated with off-label use of 
rituximab may provide useful information to improve prescribing decisions in 
clinical practice.  
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Table 1. Indications for rituximab off-label use and available evidence when it 
was requested 
Indication n (%) Level of 
evidence 
Ongoing 
studies 
Systemic lupus erythematosus 
- Lupus nephritis  
- Systemic lupus erythematosus (without nephritis) 
Chronic lymphocytic leukemiaa 
Idiopathic thrombocytopenic purpura 
Large B-cell non-Hodgkin lymphomaa 
Membranous glomerulonephritis 
Membranoproliferative/mesangiocapillary glomerulonephritis 
Mantle-cell non-Hodgkin lymphoma 
Neuromyelitis optica 
Follicular non-Hodgkin lymphomaa 
Minimal change glomerulonephritis 
Desensitization anti-HLA before transplantation 
Marginal zone non-Hodgkin lymphoma 
Thrombotic thrombocytopenic purpura 
Otherb 
 
18 (17.8) 
8 (7.9) 
11 (10.9) 
10 (9.9) 
7 (6.9) 
7 (6.9) 
6 (5.9) 
6 (5.9) 
5 (5.0) 
4 (4.0) 
3 (3.0) 
2 (2.0) 
2 (2.0) 
2 (2.0) 
10 (9.9) 
 
2b 
2b 
2a 
2b 
2b 
2b 
4 
1a 
4 
1a 
4 
2b 
4 
4 
4c 
 
Phase 3 
Phase 3 
Phase 3 
Phase 3 
Phase 3 
Phase 3 
Phase 2 
Phase 3 
Phase 1 
Phase 3 
Phase 2 
Phase 2 
Phase 2 
Phase 3 
d 
Total 101 (100)  
a Cases of chronic lymphocytic leukemia, large B-cell non-Hodgkin lymphoma, and follicular non-Hodgkin 
lymphoma included in the study were off-label conditions when rituximab use was requested. 
b Included two cases of marginal zone lymphoma of different localization (one conjunctival and other 
splenic) and one case of dermatomyositis, multi-centric Castleman's disease, fibrillary glomerulonephritis, 
focal-segmental glomerulonephritis, myelopathy of unknown cause, antiphospholipid syndrome, small cell 
non-Hodgkin lymphoma, and myasthenia gravis indications.  
c
 Level 4 for all the other conditions, but level 5 in myelopathy of unknown cause, and level 2b in small cell 
non-Hodgkin lymphoma. 
d Ongoing phase 2 clinical trials were available for dermatomyositis, focal-segmental glomerulonephritis, 
splenic marginal zone lymphoma, antiphospholipid syndrome, and myasthenia gravis, and ongoing phase 
3 clinical trials for small cell non-Hodgkin lymphoma. No ongoing clinical trials were identified for 
conjunctival marginal zone lymphoma, multi-centric Castleman's disease, fibrillary glomerulonephritis, and 
myelopathy of unknown cause,  
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Table 2. Observed outcome according to the disease 
 Short-terma Long-terma 
 
Indicationb 
NR 
n (%) 
PR 
n (%) 
CR 
n (%) 
Total* NR 
n (%) 
PR 
n (%) 
CR 
n (%) 
Total# 
Systemic lupus erythematosus 
- Lupus nephritis  
- Systemic lupus erythematosus (without nephritis)  
Chronic lymphocytic leukemia 
Idiopathic thrombocytopenic purpura 
Mantle-cell non-Hodgkin lymphoma 
Membranoproliferative/mesangiocapillary glomerulonephris. 
Membranous glomerulonephritis 
Large B-cell non-Hodgkin lymphoma 
Follicular non-Hodgkin lymphoma 
Neuromyelitis optica 
Minimal change glomerulonephritis 
Desensitization anti-HLA before transplantation 
Thrombotic thrombocytopenic purpura 
Otherc 
 
4 (22.2) 
0 
4 (36.4) 
3 (50) 
1 (16.7) 
2 (33.3) 
0 
3 (60) 
0 
2 (50) 
1 (33.3) 
0 
0 
7 (63.6) 
 
5 (27.8) 
4 (50) 
3 (27,2) 
1 (16.7) 
3 (50) 
1 (16.7) 
4 (66.7) 
0 
2 (50) 
2 (50) 
2 (66.7) 
0 
0 
3 (27.3) 
 
9 (50) 
4 (50) 
4 (36.4) 
2 (33.3) 
2 (33.3) 
3 (50) 
2 (33.3) 
2 (40) 
2 (50) 
0 
0 
2 (100) 
2 (100) 
1 (9.1) 
 
18 (100) 
8 (100) 
11 (100) 
6 (100) 
6 (100) 
6 (100) 
6 (100) 
5 (100) 
4 (100) 
4 (100) 
3 (100) 
2 (100) 
2 (100) 
11 (100) 
 
5 (27.8) 
3 (37.5) 
8 (72.7) 
4 (66.7) 
6  (100) 
3 (50) 
1 (16,7) 
4 (80) 
1 (25) 
2 (50) 
1 (33.3) 
0 
0 
9 (90) 
 
4 (22.2) 
3 (37.5) 
1 (9.1) 
0 
0 
0 
3 (50) 
0 
2 (50) 
2 (50) 
1 (33.3) 
0 
0 
1 (10) 
 
9 (50) 
2 (25) 
2 (18.2) 
2 (33.3) 
0 
3 (50) 
2 (33.3) 
1 (20) 
1 (25) 
0 
1 (33.3) 
2 (100) 
2 (100) 
1 (10) 
 
18 (100) 
8 (100) 
11 (100) 
6 (100) 
6 (100) 
6 (100) 
6 (100) 
5 (100) 
4 (100) 
4 (100) 
3 (100) 
2 (100) 
2 (100) 
11 (100) 
a
 Short-term  after a median period of 3 months (IQR 2-4), and long-term after a median of 23 months (IQR 12-30). 
NR: No response; PR: Partial response; CR: Complete response. 
b
 Patients to whom rituximab was not administered or lost in follow-up have been excluded: Idiopathic thrombocytopenic purpura (4), large B-cell non-Hodgkin lymphoma (2), 
cutaneous marginal zone non-Hodgkin lymphoma (1), membranous glomerulonephritis (1), and neuromyelitis optica (1). 
c
 Short-term response for other diseases: Dermatomyositis, multi-centric Castleman's disease, fibrillary GN, focal-segmental GN, conjunctival marginal zone lymphoma, 
myelopathy (unknown cause), and antiphospholipid syndrome (NR); small cell non-Hodgkin lymphoma, splenic marginal zone lymphoma, and myasthenia gravis (PR); 
cutaneous marginal zone non-Hodgkin lymphoma (CR). 
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Table 3. Demographics and clinical course of patients with diseases often treated with rituximab 
Indication (number of 
patients treated)a 
Age 
[median 
(IQR)]. 
Sex 
Main clinical 
and/or 
biochemical 
characteristic 
before rituximab 
treatment 
Previous treatments Rituximab  
regimen 
Time of 
short-
term 
follow 
up 
[median 
(IQR)] 
Definition of 
outcome  
 
Median 
time of 
long-term 
follow up 
[median 
(IQR)] 
Last visit:  
patients with  
response [n (%)], and 
their treatment 
Lupus nephritis 
(n=18)b 
30 y 
(25-36). 
67% F 
24 h proteinuria 
>2.5 g (≥5 g in 9 
cases). 
Refractory to 
immunosuppressive agents 
(including corticosteroids):  
- ≥ 3 drugs: 8 patients. 
- 2 drugs: 5 patients.  
All patients had received 
mycophenolate. 
1 g IV 2 weeks apart 
(95% of cases). 
4 mo  
(2.5-6) 
CR: proteinuria ≤ 
500 mg/24 h. 
PR: improvement 
≥ 50% of 24 h 
proteinuria. 
21 mo 
(15.5-
25.5) 
13 (72.2%). 
Treatment with 
immunosuppressive 
agents (one of them 
was always 
mycophenolate): 
- 3 drugs: 1 patient  
- 2 drugs:  8 patients (1 
of them also with 
additional doses of 
rituximab).  
- 1 drug (2 patients) 
- No treatment (2) 
Systhemic lupus 
erythematosus 
without nephritis 
(n=8) 
43 y  
(33.5-53). 
87.5% F 
SLEDAI >6 in 5 
cases. 
All patients treated with at 
least 3 immunosuppressive 
agents (62.5% with 4 or 
more). 
1 g IV 2 weeks apart. 4 mo 
(2-4) 
CR: clinical 
remission. 
PR: improvement 
26 mo 
(24.5-35) 
5 (62.5%). 
- Treatment with 
corticosteroids and 
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≥50% of SLEDAI.  another 
immunosuppressive 
agent  
 
Chronic lymphocytic 
leukemia (n=11) 
 
 
 
70 y 
(57-77.5). 
54.5% M 
All cases with 
relapsed/refractory 
disease . 63.6% 
high risk and 36.4% 
intermediate risk 
diseasec. 
- 9 patients previously 
treated with ≥2 
chemotherapeutic 
regimens. 
375 mg/m2 (1-6 
cycles), with other 
drugs (fludarabine, 
mitoxantrone, 
bendamustin, 
cyclophosphamide, 
and/or pentostatin). 
3 mo 
(2-4) 
CR: no symptoms 
and normalization 
of lymph nodes, 
spleen, liver and 
biochemics. 
PR: decrease of 
node size ≥50%, 
and blood count 
improvement. 
11 mo 
(8-21) 
3 (27.3%) 
- Intravenous 
immunoglobulin (1) 
- 2 patients with no 
treatment, one of them 
underwent an 
hematopoietic stem 
cell transplantation 
Mantle-cell non-
Hodgkin lymphoma 
(n=6) 
70.5 y 
(61-77). 
83% M 
Lymphadenopathies 
(± extranodal 
involvement). 
- 5 patients (83.3%) 
previously treated with R-
EPOCH (2 of them also 
with other regimens) 
-  Cyclophosphamide, 
vincristine, and 
dexamethasone (1 patient). 
375 mg/m2 (3-8 
cycles). 
6 mo 
(3.5-7.5) 
CR: 
Disappearance of 
all evidence of 
disease. 
PR: Regression of 
measurable 
disease, decrease 
of lymph node size 
≥50%.  
13.5 mo 
(6-25) 
 
Idiopathic 
thrombocytopenic 
purpura (n=6) 
73 y 
(41-78). 
67% F 
Platelet count  
≤ 20 x 109/L (66.7% 
of patients < 10 x 
109/L). 
All 6 patients treated with 
corticosteroids, 5 of them 
also with immunoglobulins 
and 1 with plasmapheresis. 
1 g IV 2 weeks apart 
(50% of cases) and 
375 mg/m2 weekly ( 
4 doses) 
1,25 mo 
(0.5-2) 
CR: platelet count 
> 150 x 109/L. 
PR: platelet count 
> 50 x 109/L. 
29 mo 
(22-41.5) 
2 (33.3%). 
- Intravenous 
immunoglobulin (1) 
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Another 
immunosuppressive agent 
in 3 cases.  
- No treatment (1) 
Membranous 
glomerulonephritis 
(n=6) 
50 y  
(41-60). 
67% M 
24 h proteinuria (> 3 
g in 5 cases). 
Tacrolimus and 
corticosteroids ± ACE 
inhibitors, furosemide. 
1 g IV 2 weeks apart 
(66.6% of cases). 
3 mo 
(2-3) 
CR: proteinuria ≤ 
500 mg/24 h. 
PR: improvement 
≥ 50% of 24 h 
proteinuria. 
25 mo 
(20-26) 
5 (83.3%). 
- Additional infusions of 
rituximab: 2 patients 
(one of them also with 
tacrolimus and 
prednisone) 
- Cyclophosphamide 
and corticosteroids (1) 
- No treatment (2) 
Membranoproliferativ
e/mesangiocapillary 
glomerulonephritis 
(n=6) 
 
50.5 y 
(36-56). 
67% F 
24 h proteinuria( > 5 
g in 4 cases). 
5 patients treated with ≥2 
immunosuppressive agents 
(± ACE inhibitors, 
furosemide). Enalapril (1).  
375 mg/m2 weekly ( 
4 doses); (67% of 
cases). 
2 mo CR: proteinuria ≤ 
500 mg/24 h. 
PR: improvement 
≥ 50% of 24 h 
proteinuria. 
38 mo 
(38-42) 
3 (50%). 
- Furosemide, 
telmisartan and 
doxazosin (1) 
- No treatment (2) 
Large B-cell non-
Hodgkin lymphoma 
(n=5) 
 
 
52 y 
(57-62) 
60% M 
Lymphadenopathies 
(± extranodal 
involvement). 
Relapsed/refractory 
disease in all patients, 60% 
previously treated with ≥3 
chemotherapeutic 
regimens. 
375 mg/m2 (1-6 
cycles), with 
gemcitabine and 
oxaliplatin (and 
ifosfamide in 1 
case).  
3 mo 
(2-3) 
CR: 
Disappearance of 
all evidence of 
disease. 
PR: Regression of 
measurable 
disease, decrease 
of lymph node size 
9 mo 
(8-10) 
1 (20%) 
- No treatment 
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≥50%. 
Follicular non-
Hodgkin lymphoma 
(n=4) 
 
77 y 
(60.5-78) 
50%M/ 
50%F 
Lymphadenopathies 
(± extranodal 
involvement). 
Relapsed/refractory 
disease in all patients, 75% 
previously treated with ≥3 
chemotherapeutic 
regimens. 
375 mg/m2 (2-6 
cycles), with 
bendamustin (and 
mitoxantrone in 1 
case). 
4.5 mo 
(3-6) 
CR: 
Disappearance of 
all evidence of 
disease. 
PR: Regression of 
measurable 
disease, decrease 
of lymph node size 
≥50%.  
26.5 
(12.5-33) 
3 (75%) 
- Maintenance therapy 
with rituximab (1) 
- No treatment (2) 
Neuromyelitis optica 
(n=4) 
 
47 y 
(38-52). 
75% F 
Refractory 
neuromyelitis. 
- 3 patients (75%) received 
before 3-4 treatments 
(immunosuppressive and 
immunomodulatory 
agents).  
- Interferon (1). 
 375 mg/m2 weekly ( 
3-4 doses); (50% of 
cases). 
2.5 mo 
(1-4) 
CR: clinical 
remission. 
PR: improvement 
or stabilization of 
symptoms. 
25 mo 
(13-29.5) 
2 (50%). 
-  Additional doses of 
rituximab (1) 
- No treatment (1) 
Minimal change 
glomerulonephritis 
(n=3) 
43 y  
(38-50). 
67% M 
24 h proteinuria 
(>1,5 g in 2 cases; 
edemas in the other 
one, but not 
quantified). 
- Corticosteroids and 
mycophenolate +/- ACE 
inhibitor (2). 
- Cyclosporin (1). 
375 mg/m2 weekly ( 
2-4 doses); (66.6% 
of cases). 
2 mo 
(1.25-3) 
CR: proteinuria ≤ 
500 mg/24 h. 
PR: improvement 
≥ 50% of 24 h 
proteinuria. 
25 mo 
(24.5-28) 
2 (66.6%). 
- No treatment 
Desensitization anti-
HLA before 
transplantation (n=2) 
41.5 y 
(41-42). 
50% M/ 
50% F 
Presence of 
antibody anti-HLA 
before 
transplantation. 
 1 g IV 2 weeks apart 
(50% of cases) 
Intravenous 
immunoglobulin and 
plasmapheresis (2). 
 CR: No reject. 
PR: Analytical 
response. 
23 mo 
(18-28) 
2 (100%). 
- No treatment (2) 
24 
 
Thrombotic 
thrombocytopenic 
purpura (n=2) 
 
47 y 
(39-55). 
50% M/ 
50% F 
Platelet count  
≤ 20 x 109/L. 
Plasmapheresis ± 
corticosteroids. 
375 mg/m2 weekly 
(2-4 doses). 
 
0.75 mo 
(0.5-1) 
CR: platelet count 
> 150 x 109/L. 
PR: Platelet count 
> 50 x 109/L. 
16 mo 
(1-31) 
2 (100%). 
Plasmapheresis and 
additional doses of 
rituximab in 1 case. 
a
 Data of indications with only one case are not shown.  
b
 One case of lupus nephritis also had hemolytic anaemia (haemoglobin 6 g/dL) that was resolved after treatment.  
c
 Stage according to the modified Rai classification. 
IQR: Interquartile range; CR: Complete response; PR: Partial response; R-EPOC: rituximab, etoposide, prednisone, vincristine, and doxorubicin. 
